NAD+ and Longevity: What the Science Actually Shows (2026)

Nicotinamide adenine dinucleotide, universally known as NAD+, is a coenzyme present in every living cell. It sits at the centre of hundreds of metabolic reactions, shuttling electrons during the conversion of food into usable energy, facilitating DNA repair, regulating gene expression and supporting immune function. Without adequate NAD+, the basic machinery of cellular life slows down. This is not a fringe theory or a marketing claim; it is textbook biochemistry that has been understood for decades and refined through thousands of published studies.

What has propelled NAD+ into the longevity spotlight is a more recent observation: NAD+ levels decline substantially with age. Research suggests that by age 50, circulating NAD+ may have fallen by roughly half compared with younger years. This decline is not trivial. Two enzyme families that are critical to healthy ageing depend directly on NAD+ availability. Sirtuins, a group of seven proteins sometimes called longevity regulators, use NAD+ to manage DNA repair, control inflammation and influence how genes are switched on and off. PARPs, the other key family, consume NAD+ to orchestrate the cellular stress response and patch breaks in DNA strands. When NAD+ runs low, both systems are compromised, and the downstream consequences read like a catalogue of ageing itself.

Specifically, depleted NAD+ impairs mitochondrial function, the energy-producing capacity of each cell. It reduces the fidelity and speed of DNA repair. It tips the immune system towards chronic, low-grade inflammation, a state researchers call inflammaging. And it accelerates cellular senescence, the process by which cells stop dividing and begin secreting harmful signals to their neighbours. In short, NAD+ decline is not merely correlated with ageing; it appears to be mechanistically intertwined with it. That connection is what makes NAD+ supplementation and therapy such a compelling research target, and also what makes it so important to distinguish between what the science has actually proven and what remains hopeful extrapolation.

If you have read anything about NAD+ and longevity, you will almost certainly have encountered the animal research, and it is genuinely impressive. Studies in rodents have demonstrated that boosting NAD+ levels can improve mitochondrial function, increase muscular strength and exercise performance, reduce systemic inflammation and enhance metabolic health. Old mice given NAD+ precursors have shown physiological improvements that, on the surface, look like a partial reversal of certain age-related declines. These findings have been replicated across multiple laboratories and published in high-quality journals, lending them real scientific weight.

Dr Samuel Klein, a respected metabolic researcher, captured the state of play with a phrase that deserves to be quoted in full: in rodents and mice, not in humans, NAD+ is miraculous. That distinction is not a minor footnote; it is the central tension in the entire NAD+ longevity conversation. Animal models are invaluable for generating hypotheses and understanding biological mechanisms, but the history of medicine is littered with interventions that performed beautifully in mice and failed to translate to people. Rodent metabolism is faster, their lifespans are shorter, and their response to supplements can differ profoundly from ours.

None of this means the animal data should be dismissed. It provides a strong biological rationale for investigating NAD+ in humans, and it has been the engine behind a surge in clinical trials. But it does mean that anyone citing rodent studies as proof that NAD+ therapy works for human longevity is skipping a step that science has not yet completed. The question is not whether NAD+ matters biologically, because it clearly does, but whether artificially boosting it in a living, ageing human body produces the same cascade of benefits observed in a laboratory mouse. That question can only be answered by human trials, and those tell a more nuanced story.

Human research into NAD+ augmentation has accelerated considerably since 2020, though it remains in what most researchers would describe as the early stages. The vast majority of clinical trials have focused on oral precursors, principally nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN), rather than on intravenous NAD+ itself. These precursors are molecules that the body can convert into NAD+, and they have the practical advantage of being easy to administer, relatively affordable and amenable to the kind of placebo-controlled trial design that produces reliable evidence.

The results so far are a genuine mixed bag, and intellectual honesty requires saying so plainly. On the positive side, studies have found benefits for specific populations: NR supplementation showed meaningful improvements in women with prediabetes, NMN produced encouraging results in patients with Parkinson's disease, and NAD+ precursors have demonstrated benefit in peripheral artery disease. These are real findings published in peer-reviewed journals. However, the broader metabolic health trials, the ones testing whether NAD+ boosters can improve insulin sensitivity, body composition, exercise capacity or general markers of ageing in otherwise healthy adults, have largely failed to replicate the dramatic improvements seen in animals.

Dr Shalender Bhasin, an endocrinologist involved in NAD+ research, put it plainly: we are still in the early stages of human studies. That assessment was echoed in 2025 by a landmark review published in Nature Aging, authored by more than 25 scientists from institutions including the University of Oslo, Harvard Medical School, the Buck Institute for Research on Aging, the University of Copenhagen and Chiba University. The review concluded that NAD+ augmentation shows clear biological activity, meaning it does measurably change biomarkers and cellular processes, but that clinical effectiveness remains inconclusive across studies. A 2026 PRISMA-compliant systematic review examining 113 studies reached the same conclusion: biological activity confirmed, anti-ageing effectiveness inconclusive. As researcher Christopher Martens observed, the cart may be well ahead of the horse.

Of all the ways to boost NAD+ levels, intravenous infusion is the most commercially visible, the most expensive and, paradoxically, the one with the least clinical evidence behind it. Walk into any longevity or wellness clinic in Dublin, Cork or most major cities worldwide and you will find NAD+ IV drips on the menu, typically at €250 to €500 per session in Ireland and up to €1,000 or more at premium international providers. The treatment involves a slow intravenous infusion of 250 to 500mg of NAD+ delivered over two to four hours, considerably longer than a standard vitamin drip because pushing NAD+ too quickly causes pronounced side effects.

The rationale for the IV route is bioavailability. Proponents argue that delivering NAD+ directly into the bloodstream bypasses digestive breakdown and achieves higher circulating levels than any oral supplement could. There is some pharmacological logic to this argument, but it also raises questions that the current evidence cannot answer. It remains unclear how much of the infused NAD+ actually reaches cells intact versus being metabolised in the blood before it can be used. The molecule is large and subject to rapid enzymatic breakdown, and some researchers suspect that even intravenously delivered NAD+ is substantially converted to its precursors before cellular uptake occurs.

More critically, there are no eligible outcome trials examining IV NAD+ for anti-ageing indications. This is a remarkable gap given how widely the treatment is marketed for longevity, energy and cellular rejuvenation. The evidence base for IV NAD+ consists largely of anecdotal reports, mechanistic reasoning borrowed from the precursor trials, and a small number of observational or pilot studies that lack the rigour needed to draw firm conclusions. Side effects are also more common with the IV route and can include gastrointestinal symptoms such as cramping, diarrhoea, nausea and vomiting, as well as flushing, chest tightness and palpitations during the infusion. None of this makes IV NAD+ dangerous when administered properly, but it does mean that the commercial enthusiasm surrounding this particular delivery method has substantially outpaced the clinical evidence supporting it. Neither IV nor oral NAD+ is approved by the FDA, the HPRA or any major regulatory body to treat or prevent any disease.

For anyone interested in NAD+ for longevity, oral precursors represent the more evidence-supported and financially sustainable option. Nicotinamide riboside and nicotinamide mononucleotide are both naturally occurring molecules that the body converts into NAD+ through well-characterised enzymatic pathways. They are widely available as supplements and typically cost between €30 and €80 per month, a fraction of the price of even a single IV session.

NR has the more established safety and trial record of the two. It has been the subject of more than 12 published clinical trials and has been demonstrated safe at doses up to 2,000mg daily for 12 weeks, with no serious adverse events reported. The research base includes studies examining its effects on blood NAD+ levels, cardiovascular function, metabolic markers and neurodegenerative conditions. While the results have been mixed in terms of hard clinical endpoints, NR consistently and reliably raises blood NAD+ levels, confirming that oral supplementation can achieve the basic biochemical goal of NAD+ repletion.

NMN has a smaller but rapidly growing body of clinical evidence. Dosing in published trials has ranged from 250mg to 1,200mg daily, and early results have been encouraging in specific populations. NMN has attracted particular interest in Japan, where some of the most rigorous trials have been conducted, and it benefits from a slightly more direct metabolic pathway to NAD+ than NR in certain tissues. The honest assessment of both precursors is that they are biologically active, generally safe and capable of raising NAD+ levels, but that neither has yet been shown to meaningfully slow ageing or extend healthspan in well-designed human trials. They remain promising tools under active investigation rather than proven longevity interventions.

NAD+ supplementation, whether oral or intravenous, is generally well tolerated in healthy adults at the doses studied to date. The most common side effects with oral precursors are mild and gastrointestinal in nature: occasional nausea, bloating or digestive discomfort, usually at higher doses and often resolving as the body adjusts. IV NAD+ carries a somewhat higher side-effect burden because of the infusion process itself, with cramping, flushing, nausea, vomiting and temporary cardiovascular symptoms such as palpitations all reported, particularly when the drip rate is too fast.

One safety question that deserves direct discussion is the potential relationship between NAD+ and cancer. Cancer cells, like all rapidly dividing cells, have high metabolic demands and consume substantial amounts of NAD+. A 2020 analysis raised the theoretical concern that artificially boosting NAD+ levels could, in principle, fuel the growth of existing cancers or pre-cancerous cells by supplying them with the metabolic currency they need to proliferate. This is a legitimate area of scientific inquiry rather than a settled risk, and it is important to be proportionate about it. To date, no definitive human evidence has emerged showing that NAD+ supplementation increases cancer risk in healthy individuals, and the precursor trials have not reported elevated cancer incidence.

However, the question has not been definitively resolved either, and long-term safety data beyond 12 weeks of high-dose supplementation remain limited. For this reason, most researchers advise caution in individuals with a current cancer diagnosis or a strong family history of certain cancers, and suggest discussing NAD+ supplementation with an oncologist in those circumstances. The broader point is that NAD+ therapy, in any form, is not something to approach casually or without medical awareness. It is a biologically active intervention, and biological activity cuts both ways.

One of the most important and frequently overlooked aspects of the NAD+ conversation is that your body already has robust, well-understood mechanisms for maintaining and boosting its own NAD+ levels, and these mechanisms respond powerfully to lifestyle choices that cost nothing. Exercise is perhaps the single most effective natural NAD+ booster available. Physical activity increases the expression of NAMPT, the rate-limiting enzyme in the NAD+ salvage pathway, effectively upregulating your body's own NAD+ production machinery. Regular aerobic exercise and resistance training have both been shown to raise NAD+ levels and improve the downstream processes, mitochondrial function, inflammation control and cellular repair, that NAD+ supplementation is designed to support.

Nutrition also plays a meaningful role. Foods rich in NAD+ precursors include meat, fish, legumes, whole grains and certain vegetables. A varied, whole-food diet provides tryptophan, niacin and other building blocks that feed into NAD+ biosynthesis pathways. While no single food will raise your NAD+ levels as dramatically as a supplement or an infusion, a consistently good diet creates the substrate foundation that your cells need. Sleep optimisation matters too: disrupted sleep and circadian rhythm misalignment have been linked to impaired NAD+ metabolism, and restoring healthy sleep patterns supports the natural oscillation of NAD+ levels that tracks the body's internal clock.

Caloric moderation, whether through mindful eating, time-restricted feeding or periodic caloric restriction, has been shown in both animal and human studies to activate sirtuin pathways and improve NAD+ metabolism. The irony of the NAD+ supplement market is that the lifestyle interventions most likely to maintain healthy NAD+ levels are the same ones that promote longevity through dozens of other mechanisms simultaneously. Exercise, nutrition, sleep and caloric moderation are not glamorous, they cannot be sold at €400 a session, and they require sustained effort rather than a comfortable hour in a clinic chair. But the evidence supporting them is vastly stronger than the evidence for any NAD+ product currently on the market, and any credible longevity strategy should treat them as the foundation rather than an afterthought.

Pulling together the full weight of the evidence, the honest position on NAD+ and longevity in 2026 is one of informed optimism tempered by scientific humility. The biology is real and compelling. NAD+ genuinely declines with age, that decline genuinely impairs critical cellular processes, and restoring NAD+ levels genuinely produces measurable biological effects in both animals and humans. These are not contested points, and anyone who dismisses NAD+ as pure hype is ignoring a substantial body of serious science.

But the leap from biological activity to clinical benefit has not yet been made convincingly for any NAD+ intervention in the context of human ageing. The two most comprehensive reviews to date, a 2025 Nature Aging consensus by leading researchers from five countries and a 2026 PRISMA systematic review of 113 studies, both reached the same verdict: clear biological activity, inconclusive clinical effectiveness. That word, inconclusive, is not a rejection; it is a statement that we do not yet have enough well-designed, adequately powered human trials to know whether NAD+ therapy translates into longer, healthier lives. The research pipeline is active and growing, and the next few years may well change the picture substantially.

For individuals considering NAD+ therapy today, the practical takeaway is to match your expectations and spending to the current state of the evidence. Oral precursors such as NR and NMN offer a relatively affordable, well-tolerated way to explore NAD+ augmentation, backed by a meaningful if incomplete trial record. IV NAD+ therapy provides a more intensive experience but at considerably higher cost and with considerably less clinical evidence, particularly for longevity indications. Whichever route interests you, it should sit on top of a foundation of exercise, good nutrition, quality sleep and stress management, never as a replacement for it. And if you are exploring NAD+ therapy at a clinic in Ireland, choose a provider where a qualified healthcare professional conducts a proper assessment, discusses the limitations of the evidence honestly, and monitors you throughout the treatment.